Breaking News, Financial News

Gilead’s 4Q Financial Results

HIV portfolio drives growth with flagship Biktarvy and oncology revenues driven by cell therapy franchise and Trodelvy.

Gilead 4Q Revenues: $7.4 billion (+2%) 4Q Earnings: $1.6 billion (earnings were $376 million 4Q21) FY Revenues: $27.3 billion (flat) FY Earnings: $4.6 billion (-26%) Comments: Total fourth quarter revenue of $7.4 billion up 2% primarily due to increased sales in Oncology, HIV and hepatitis C virus (HCV), partially offset by lower Veklury (remdesivir) sales. Total product sales excluding Veklury rose 9% to $6.3 billion. Veklury sales decreased 26% to $1.0 billion for the quarter and decre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters